(MedPage Today) -- More phase III results showed that Amgen's investigational PCSK9 inhibitor evolocumab significantly reduced LDL cholesterol within 12 weeks, this time in patients who were also taking a statin, the drugmaker announced. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment